Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
| Revenue (TTM) | $316.70M |
| Gross Profit (TTM) | $307.70M |
| EBITDA | $-9.90M |
| Operating Margin | 66.40% |
| Return on Equity | 1.59% |
| Return on Assets | -1.01% |
| Revenue/Share (TTM) | $4.75 |
| Book Value | $8.61 |
| Price-to-Book | 1.04 |
| Price-to-Sales (TTM) | 1.90 |
| EV/Revenue | 0.084 |
| EV/EBITDA | -1.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1015.00% |
| Shares Outstanding | $64.52M |
| Float | $56.81M |
| % Insiders | 7.80% |
| % Institutions | 84.29% |
Volatility is currently expanding
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.
Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that will make a meaningful difference across the Greater New Haven area and beyond.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARVN and any ticker you trade — then tracks every position and per-strategy win rate.
